EANS-News: NOXXON Pharma AG announces management changes

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Company Information

Berlin, Germany, June 28, 2010 (euro adhoc) - NOXXON Pharma AG,
Berlin, Germany announced today that CEO Dr Frank Morich will leave
the company effective August 15, 2010 to take up the position
Executive Vice President, International Operations, at Takeda
Pharmaceutical Company Limited.

Iain Buchanan, who worked with the Board of Directors since 2007 and
later became a Director of NOXXON Pharma AG , will assume the role of
Interim CEO with effect from September 1, 2010, and will support the
board during its search for a permanent replacement.

Iain has an impressive track record and brings to NOXXON over 30
years of experience in the pharmaceutical and biotech industry. He
comes to NOXXON from Novexel in Paris where, earlier this year, he
was responsible for the sale of the company to Astra Zeneca. Prior
to his role as CEO of Novexel Iain has held a range of management and
business development positions within a number of companies in the
pharmaceutical industry including Vertex, Johnson and Johnson,
Biogen, and Merck & Co.

Dr Walter Wenninger, Chairman of the Board of NOXXON Pharma AG
comments: " Under Frank Morich´s leadership, NOXXON has made the
successful transition into a development stage company with two
compounds already in clinical development, an interesting preclinical
pipeline, and future funding secured. The board joins me in thanking
Frank for his achievements and we all wish him well in his new
appointment." He continues: " We are grateful to Iain for his
willingness to act as Interim CEO and are certain his management
skills and professional experience will ensure continuity and future
success for NOXXON and its entire dedicated team."

About NOXXON Berlin-based NOXXON Pharma AG is a clinical stage
biotechnology company focusing on the development of Spiegelmers® for
the treatment of various disease indications. NOXXON is in possession
of a broad patent estate and has access to a readily scalable GMP
production. In addition to its in-house programs, NOXXON discovers
and develops Spiegelmers® in collaboration with partners from the
pharmaceutical industry, including Eli Lilly and Hoffmann La-Roche.
The business strategy of NOXXON is to broaden this range of
collaborations through co-development and licensing agreements for
the proprietary clinical and pre-clinical products. Currently, the
company has two compounds in clinical development. The declared goal
of NOXXON is to establish its oligonucleotide-based drug discovery
platform (Spiegelmers®) as the leading "scaffold" technology to
create new chemical entities with superior properties.

Webseite: http://www.noxxon.com

General contact:
Emmanuelle Delabre
NOXXON Pharma AG
Max-Dohrn-Strasse 8-10
10589 Berlin, Germany

Phone: + 49-30-726247-100
FAX: + 49-30-726247-225
Email: edelabre@noxxon.com

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Deutsche Effecten- und Wechsel-Beteiligungsges. AG (DEWB)
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Marco Scheidler

Tel.: +49 (0) 3641 573-3600

E-Mail: marco.scheidler@dewb-vc.com

Branche: Financial & Business Services
ISIN: DE0008041005
WKN: 804100
Börsen: Berlin / free trade
Stuttgart / free trade
München / free trade
Frankfurt / Open Market / Entry Standard